Biomarkers in axial spondyloarthritis

Current Opinion in Rheumatology

Volumn 27, Issue 4, 2015, Pages 343-348

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Axial spondyloarthritis; Biomarker; Magnetic resonance imaging radiography; Validation

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CARBOXY TERMINAL TELOPEPTIDE; HLA ANTIGEN CLASS 2; HLA B27 ANTIGEN; INTERLEUKIN 6; INTERMEDIATE FILAMENT PROTEIN; PENTRAXIN 3; STROMELYSIN; VASCULOTROPIN; VIMENTIN;

ANGIOGENESIS; AXIAL SPONDYLOARTHRITIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; SPONDYLARTHRITIS; BLOOD; HUMAN; PROCEDURES; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; C-REACTIVE PROTEIN; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS;

EID: 84942589621     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000180     Document Type: Review

References (50)

1. Baraliakos X, Baerlecken N, Witte T, et al. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 2014;73:1079-1082
2. Baerlecken NT, Nothdorft S, Stummvoll GH, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 2014;73:1211-1214.
3. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16.
4. Machado P, Landewe RB, Braun J, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012;71:2002-2005.
5. Weis A, Song IH, Haibel H, et al. Good correlation between changes in objective and subjective signs of inflammation in patients with short-but not long duration of axial spondyloarthritis treated with tumor necrosis factorblockers. Arthritis Res Ther 2014;16:R35.
6. Maksymowych WP, Van Der Heijde D, et al. Relationship between MRI and clinical remission patients with nonradiographic axial spondyloarthritis after two years of adalimumab therapy. J Rheumatol 2014;41:1496.
7. Gong Y, Zheng N, Chen S, et al. Ten years experience on needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 2012;64:1399-1406.
8. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135-140.
9. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58:3413-3418.
10. Appel H, Loddenkemper C, Grozdanovic Z, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006;8:R143.
11. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008;10:R104.
12. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
13. Van Der Heijde D, Machado P, Braun J, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:369-373.
14. Lambert RGW, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:4005-4014.
15. Maksymowych WP, Salonen D, Inman RD, et al. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 2010;37:1728-1734.
16. Toussirot E, Dumoulin G, Saas P, et al. Increased tartrate-resistant acid phosphatase serum levels in ankylosing spondylitis and relationship with the inflammatory process. Ann Rheum Dis 2008;67:430-431.
17. Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007;26:211-215.
18. Keller C, Webb A, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003;62:1128-1132.
19. Toussirot E, Saas P, Deschamps M, et al. Increased production of soluble CTLA-4 in patients with spondyloarthropathies correlates with disease activity. Arthritis Res Ther 2009;11:R101.
20. Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010;69:618-623.
21. Maksymowych WP, Rahman P, Shojania K, et al. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008;35:2030-2037.
22. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008;67:511-517.
23. Baraliakos X, Listing J, Von Der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis: evidence for major individual variations in a large proportion of patients. J Rheumatol 2009;36:997-1002.
24. Ramiro S, Stolwijk C, Van Tubergen A, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 2015;74:52-59.
25. Cortes A, Maksymowych WP, Wordsworth BP, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis 2014; Online First, published onMarch20.
26. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phasereactant levels, and cigarettesmoking statuspredictspinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388-1398.
27. Poddubnyy D, Haibel H, Listing J, et al. Cigarette smoking has a dose dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort (GESPIC). Ann Rheum Dis 2013;72:1430-1432.
28. Kroon F, Landew R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623-1629.
29. Ramiro S, Van Der Heijde D, Van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014; Online First, published on May 7.
30. Maksymowych WP, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-1853.
31. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-3262.
32. Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:572-574.
33. Clarkin CE, Gerstenfeld LC. VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct 2013;31:1-11.
34. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628.
35. Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003;132:158-162.
36. Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF alpha inhibitors. Ann Rheum Dis 2011;70:1375-1381.
37. Poddubnyy DA, Conrad K, Haibel H, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 2014;73:2137-2143.
38. De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005;206:17-27.
39. Kruithof E, De Rycke L, Vandooren B, et al. OMERACT Special Interest Group on synovial analysis in clinical trials: identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006;54:1795-1804.
40. Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 2014;73:1746-1748.
41. Bay-Jensen AC, Wichuk S, Byrjalsen I, et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS One 2013;8:e54504.
42. Tilleman K, Van Steendam K, Cantaert T, et al. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008;47:597-604.
43. Vassiliadis E, Oliveira CP, Alvares-Da-Silva MR, et al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res 2012;4:403-414.
44. Bay-Jensen AC, Karsdal MA, Vassiliadis E, et al. Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum 2013;65:972-980.
45. Maksymowych WP, Landewe R, Tak PP, et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009;36:1785-1791.
46. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237-244.
47. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-1538.
48. De Vries MK, Van Eijk IC, Van Der Horst-Bruinsma I, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Care Res 2009;61:1484-1490.
49. Turina M, Yeremenko N, Paramarta J, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther 2014;16:413
50. Baeten D, Baraliakos X, Braun J, et al. Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1705-1713.